{"classes":[{"categories":[{"measurements":[{"comment":"Could not be estimated due to the low number of events at the time of the analysis.","groupId":"OG000","lowerLimit":"11.5","upperLimit":"NA","value":"15.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"123"}],"units":"Participants"}],"description":"Overall survival (OS) is defined as the time from the first dose of any study treatment to the date of death due to any cause. Overall survival was analyzed using the Kaplan-Meier method; participants who were alive or lost to follow-up as of the data analysis cut-off date were censored at their date of last contact (last known to be alive).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received carfilzomib administered by intravenous (IV) infusion on days 1, 2, 8, 9, 15, and 16 of each 28-day cycle (20 mg/m² on days 1 and 2 of cycle 1 and 27 mg/m² thereafter). Participants also received 20 mg dexamethasone IV or orally on days 1, 2, 8, 9, 15, 16, 22, and 23.\n\nParticipants received treatment until disease progression, unacceptable toxicity, initiation of new antimyeloma therapy, withdrawal of consent, subject noncompliance, or intercurrent illness or worsening of a chronic condition, whichever occurred first.","id":"OG000","title":"Carfilzomib With Dexamethasone"}],"paramType":"MEDIAN","populationDescription":"Safety population","reportingStatus":"POSTED","timeFrame":"From first dose until the data cut-off date of 15 March 2019; median time on follow-up for survival was 15.3 months.","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}